Ruxolitinib Combined With Etanercept for Patients With Corticosteroid-Refractory Graft Versus Host Disease After Allogeneic Stem Cell Transplantation: A Multi-Center, Open-Label, Prospective Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024408

Enrollment

Unknown

Registered

2019-07-10

Start date

2018-06-30

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute and chronic graft versus host disease

Interventions

ruxolitinib group:ruxolitinib

Eligibility

Sex/Gender

All

Age

15 Years to 59 Years

Inclusion criteria

Inclusion criteria: All patients aged >= 10 years who experienced severe (grades III–IV) SR-aGVHD and corticosteroid-refractory were included.

Exclusion criteria

Exclusion criteria: Patient has received other second-line systemic treatment in addition to ruxolitinib/ etanercept for acute GVHD; The presence of active uncontrolled infection; Known human immunodeficiency virus infection; Active hepatitis B virus (HBV) or hepatitis C virus infection; Severe organ dysfunction unrelated to underlying GVHD; Currently breastfeeding.

Design outcomes

Primary

Measure	Time frame
safety;overall survival;	—

Countries

China

Contacts

Public ContactHe Huan

The First Affiliated Hospital, College of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026